KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 74 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,110,166 | +5.6% | 115,282 | -1.4% | 0.00% | 0.0% |
| Q2 2023 | $1,051,758 | +193.0% | 116,862 | +155.9% | 0.00% | – |
| Q1 2023 | $358,919 | +21.2% | 45,664 | +4.2% | 0.00% | – |
| Q4 2022 | $296,176 | -53.9% | 43,813 | -1.0% | 0.00% | -100.0% |
| Q3 2022 | $642,000 | +18.7% | 44,269 | -19.5% | 0.00% | 0.0% |
| Q2 2022 | $541,000 | +203.9% | 54,976 | +273.9% | 0.00% | – |
| Q2 2020 | $178,000 | – | 14,705 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |